State Street’s Adaptimmune Therapeutics ADAP Stock Holding History

State Street’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-426,714	Closed	-$102K	–	4285
2025 Q2	$102K	Buy	426,714 +5,422	+1%	+$1.45K	﹤0.01%	3971
2025 Q1	$83K	Buy	421,292 +21,213	+5%	+$11K	﹤0.01%	4007
2024 Q4	$216K	Buy	400,079 +3,287	+0.8%	+$2.4K	﹤0.01%	3837
2024 Q3	$377K	Buy	396,792 +5,891	+2%	+$6.68K	﹤0.01%	3650
2024 Q2	$381K	Buy	390,901 +78,363	+25%	+$86K	﹤0.01%	3623
2024 Q1	$494K	Buy	312,538 +7,202	+2%	+$8.69K	﹤0.01%	3652
2023 Q4	$242K	Buy	305,336 +6,235	+2%	+$3.52K	﹤0.01%	3851
2023 Q3	$233K	Buy	299,101 +8,127	+3%	+$6.82K	﹤0.01%	3894
2023 Q2	$269K	Buy	290,974 +6,233	+2%	+$7.43K	﹤0.01%	3916
2023 Q1	$310K	Buy	284,741 +15,943	+6%	+$24.7K	﹤0.01%	3912
2022 Q4	$392K	Sell	268,798 -40,500	-13%	-$65.6K	﹤0.01%	3853
2022 Q3	$332K	Sell	309,298 -57,227	-16%	-$105K	﹤0.01%	3928
2022 Q2	$623K	Sell	366,525 -274,095	-43%	-$471K	﹤0.01%	3751
2022 Q1	$1.32M	Buy	640,620 +25,627	+4%	+$69.2K	﹤0.01%	3719
2021 Q4	$2.31M	Buy	614,993 +47,784	+8%	+$217K	﹤0.01%	3594
2021 Q3	$2.94M	Buy	567,209 +307,627	+119%	+$1.38M	﹤0.01%	3501
2021 Q2	$1.11M	Sell	259,582 -147,905	-36%	-$718K	﹤0.01%	3649
2021 Q1	$2.16M	Buy	407,487 +47,014	+13%	+$269K	﹤0.01%	3411
2020 Q4	$1.94M	Buy	360,473 +154,691	+75%	+$840K	﹤0.01%	3390
2020 Q3	$1.64M	Buy	205,782 +33,551	+19%	+$294K	﹤0.01%	3278
2020 Q2	$1.72M	Buy	+172,231	New	+$1.08M	﹤0.01%	3238
2019 Q3	–	Sell	-38,434	Closed	-$155K	–	3806
2019 Q2	$155K	Sell	38,434 -1,019	-3%	-$4.15K	﹤0.01%	3627
2019 Q1	$170K	Sell	39,453 -1,170	-3%	-$5.45K	﹤0.01%	3590
2018 Q4	$234K	Buy	40,623 +4,350	+12%	+$32.1K	﹤0.01%	3550
2018 Q3	$492K	Hold	36,273	–	–	﹤0.01%	3483
2018 Q2	$431K	Sell	36,273 -1,480	-4%	-$18.5K	﹤0.01%	3487
2018 Q1	$424K	Sell	37,753 -63,626	-63%	-$557K	﹤0.01%	3452
2017 Q4	$678K	Sell	101,379 -821	-0.8%	-$6.34K	﹤0.01%	3411
2017 Q3	$837K	Buy	102,200 +36,400	+55%	+$227K	﹤0.01%	3410
2017 Q2	$295K	Hold	65,800	–	–	﹤0.01%	3500
2017 Q1	$363K	Hold	65,800	–	–	﹤0.01%	3429
2016 Q4	$266K	Hold	65,800	–	–	﹤0.01%	3469
2016 Q3	$464K	Hold	65,800	–	–	﹤0.01%	3302
2016 Q2	$536K	Hold	65,800	–	–	﹤0.01%	3381
2016 Q1	$535K	Hold	65,800	–	–	﹤0.01%	3339
2015 Q4	$794K	Buy	+65,800	New	+$644K	﹤0.01%	3257

Other funds holding ADAP

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

State Street's ADAP Position: Q3 2025 in Review

State Street sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 426,714 shares — an estimated $102K sold.

State Street first reported a position in ADAP in Q4 2015 and held it in 36 quarters. The position peaked at $2.94M in Q3 2021. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

State Street reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
State Street sold 426,714 Adaptimmune Therapeutics shares in Q3 2025, an estimated $102K.
State Street first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 36 quarters.
State Street's Adaptimmune Therapeutics position peaked at $2.94M in Q3 2021.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.